Research Progress on Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation -Review / 中国实验血液学杂志

ABSTRACT

Thrombocytopenia is a major complication following allogeneic stem cell transplantation(allo-HSCT). Overall survival(OS) and disease-free survival(DFS) of patients with thrombocytopenia were lower than those without thrombocytopenia. Lower platelet counts before conditioning, graft-versus-host disease(GVHD) and cytomegalovirus(CMV) infection are adverse factors for the patiens with thrombocytopenia. Bone marrow microenvironment may be involved in the pathogenesis. Thrombopoietin(TPO) and mesenchymal stem cells can improve the platelet counts. In this review the definition, prognosis, pathogenesis and potential therapy for thrombocytopenia after allo-HSCT are summarized.